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Background
Brain metastases, which occur in approximately 20–40% of
individuals with systemic cancer, represent a signiﬁcant
cause of morbidity and mortality and overwhelm all other
types of brain tumors in terms of incidence and public
health impact [1]. Considerable research has focused on
improving survival and quality of life for this patient
population. Given the expanding knowledge base and the
rapid emergence of new therapies, the American Associa-
tion of Neurological Surgeons (AANS), the Congress of
Neurological Surgeons (CNS), and the AANS/CNS Joint
Tumor Section jointly funded an initiative to produce
methodologically rigorous evidence-linked clinical prac-
tice parameter guidelines on this topic. The overall objec-
tive of this series of guideline papers is to provide the latest
up-to-date evidence-based recommendations for the man-
agement of patients with brain metastases centering on
eight questions related to commonly encountered clinical
scenarios (Tables 1, 2, 3). Accomplishment of this goal
required undertaking a systematic review of the literature.
The McMaster University Evidence-based Practice
Center (EPC), which is an academic research unit partially
funded by an EPC grant from the Agency for Healthcare
Research and Quality (AHRQ), with specialized expertise
in evidence-based medicine and the development of sys-
tematic reviews, was contracted to performed the system-
atic review in consultation with the guideline panel
assembled for the initiative. The McMaster EPC also
served as facilitators during the guideline development,
consensus and writing processes.
The Joint Tumor Section of the AANS/CNS recruited
representatives from surgical neuro-oncology (including
microsurgical, stereotactic radiosurgery and experimental
therapies), radiation oncology (fractionated radiotherapy,
stereotactic radiosurgery and brachytherapy) and medical
neuro-oncology (chemotherapy and experimental thera-
pies) to form a multi-disciplinary panel of 17 clinical
experts who developed the evidence-based practice
guidelines from the systematic review results (Table 4).
These seventeen experts across several disciplines were all
nominated and selected by the Executive Committee of the
AANS/CNS Tumor Section based on their clinical exper-
tise and recognized contributions to the ﬁeld of neuro-
oncology in general and brain metastases in particular. The
Tumor Section Executive Committee then selected a
chairperson for this endeavor to organize and lead the
effort, serving also to encourage and manage debate on the
various topics involved.
Scope of the systematic review and clinical
practice guidelines
The speciﬁc questions regarding the treatment of brain
metastases addressed by the systematic review and the
resulting practice guidelines were determined collabora-
tively by the clinical guideline panel and methodologists at
the McMaster EPC. In total, eight questions were agreed
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DOI 10.1007/s11060-009-0059-2upon and these correspond to the eight practice guideline
papers in this series. Four of the questions speciﬁcally
focus on the treatment of patients with newly diagnosed
brain metastases (Table 1), one question addresses the
treatment of recurrent/progressive metastatic brain disease
(Table 2) and the remaining three questions are relevant to
all patients with brain metastases (Table 3). Some of the
questions had several parts.
For the purposes of the systematic review and the clin-
ical practice guidelines, brain metastases have been deﬁned
as solid metastases to the brain from systemic cancer. The
deﬁnition excludes leptomeningeal metastatic disease.
Table 1 Guideline questions speciﬁcally addressing treatment of
patients with newly diagnosed brain metastases
For patients with newly diagnosed brain metastases
Should whole-brain radiation therapy (WBRT) be used as the sole
therapy in patients with newly diagnosed, surgically accessible,
single brain metastases, compared with WBRT plus surgical
resection, and in what clinical settings?
Comparisons include:
– WBRT vs. WBRT ? surgical resection
If WBRT is used, is there an optimal dosing/fractionation schedule?
Comparisons include:
– Dose/fractionation schedule 1 vs. dose/fractionation schedule 2
If WBRT is used, what impact does tumor histopathology have on
treatment outcomes?
– Any study evaluating the outcome of WBRT by tumor
histopathology (e.g., radiation-sensitive tumors vs. radiation-
resistant tumors) in patients with newly diagnosed metastatic
brain tumors
Should patients with newly diagnosed metastatic brain tumors
undergo open surgical resection versus radiosurgery or other
treatment modalities, and in what clinical settings?
Comparisons include:
– Surgical resection vs. WBRT
– Surgical resection vs. surgical resection ? WBRT
– Surgical resection ± WBRT or local RT vs. stereotactic
radiosurgery (SRS) ± WBRT or local RT
– Surgical resection vs. surgical resection ? SRS
– Surgical resection ? WBRT vs. surgical resection ? SRS
Should patients with newly diagnosed metastatic brain tumors
undergo SRS compared with other treatment modalities?
Comparisons include:
– WBRT vs. WBRT ? SRS
– SRS vs. WBRT ? SRS
– SRS vs. WBRT
– SRS ± WBRT or local RT vs. surgical resection ± WBRT or
local RT
– SRS ± surgical resection vs. WBRT ± surgical resection
– Single session SRS ± WBRT vs. fractionated SRS ± WBRT
Should patients with newly diagnosed metastatic brain tumors be
given chemotherapy for the treatment of brain metastases compared
with no chemotherapy?
Comparisons include:
Any comparative studies evaluating chemotherapy alone or in
combination with other treatment modalities for the treatment of
newly diagnosed brain metastases
Table 2 Guideline questions speciﬁcally addressing treatment of
patients with recurrent and/or progressive brain metastases
Patients with recurrent or progressive brain metastases
What evidence is available regarding the use of WBRT, SRS, surgical
resection or chemotherapy for the treatment of recurrent and/or
progressive brain metastases?
– Any study evaluating the use of WBRT, SRS, surgical excision
or chemotherapy alone or in combination in patients with
recurrent and/or progressive brain metastases
If WBRT is used, what impact does tumor histopathology have on
treatment outcomes?
– Any study evaluating the outcome(s) of WBRT by tumor
histopathology (e.g., radiation-sensitive tumors vs. radiation-
resistant tumors) in patients with recurrent and/or progressive
brain metastases
Table 3 Guideline questions addressing all patients with brain
metastases
For all patients with brain metastases
Do prophylactic anticonvulsants decrease the risk of seizure in
patients with metastatic brain tumors compared with no treatment?
Comparison: anticonvulsant prophylaxis vs. none
Do steroids improve neurologic symptoms in patients with metastatic
brain tumors compared to no treatment? If steroids are given, what
dose should be used?
Comparisons include:
– Steroid therapy vs. none
– Comparison of different doses of steroid therapy
What evidence is available regarding the following emerging/
investigational therapies for the treatment of metastatic brain
tumors?
New radiation sensitizers:
Motexaﬁn-gadolinium
RSR 13
Local modalities placed at the time of surgical excision:
Local irradiation: gliasite radiation therapy system/balloon
placement
Local chemotherapy: BCNU-impregnated polymers
Brachytherapy
New chemotherapeutic agents:
Temozolomide
Fotemustine
Molecular targeted agents:
Geﬁtinib (ZD1839)
Anti-angiogenesis agents:
Bevacizumab (Avastin)
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Abroad literaturesearchstrategy wasundertaken toidentify
all citations relevant to the management of brain metastases.
Thefollowingelectronicdatabasesweresearchedfrom1990
to September 2008: MEDLINE
, Embase
, Cochrane
Database of Systematic Reviews, Cochrane Controlled Tri-
alsRegistry,andCochraneDatabaseofAbstractsofReviews
of Effects. The search strategy used a combination of sub-
headings and text words. The speciﬁc search terms used for
MEDLINE
 are provided in Appendix A; this search strat-
egy wasmodiﬁedaccordinglyforappropriate terms foreach
database searched. Reference lists of included studies were
also screened for potentially relevant studies.
An additional electronic database search was conducted
to identify randomized trials published from 1970 forward
that evaluated different dose/fractionation schedules of
whole-brain radiation for the treatment of brain metastases.
This was done to capture seminal studies in this area known
to have been undertaken in this earlier time frame. The
initial electronic search commenced at 1990 given the lack
of any known comparative data for radiation, surgical
resection and radiosurgery prior to this date, although
additional searches were conducted as far back as 1970 as
outlined above.
Conference proceedings from the 2006–2008 meetings of
the AANS, CNS, Society for NeuroOncology (SNO), Amer-
ican Society for Therapeutic Radiation and Oncology
(ASTRO), American Society for Clinical Oncology (ASCO)
and the AANS/CNS joint section on tumors satellite sympo-
siums were searched for abstracts eligible for inclusion in the
emerging and investigational therapies guideline question.
Study selection, quality assessment and statistical
methods
The search of the bibliographic databases identiﬁed 16,966
possibly relevant citations. These citations were screened in
duplicate using an online systematic review management
system designed by TrialStat! (http://www.ESRNEXUS.
com). Two independent reviewers evaluated titles and
abstracts using a priori eligibility criteria in standardized
forms. Cases of disagreement were resolved by a third
reviewer.Thesameprocesswasappliedtofulltextscreening
of potentially relevant studies. Articles that met the eligi-
bility criteria for one or more of the questions were grouped
according to the questions they addressed. Reasons for
exclusion were documented. The eligibility criteria for each
of the eight questions are documented in the individual
clinical practice guideline papers in this series.
Table 4 Management of brain metastases guideline panel
Guideline panel members Afﬁliations
Steven N. Kalkanis, MD,
Chair
Dept. of Neurosurgery,
Henry Ford Health System, Detroit, MI
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MBA
Dept. of Neurosurgery,
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David W. Andrews, MD Dept. of Neurosurgery,
Thomas Jefferson University,
Philadelphia, PA
Anthony L. Asher, MD,
FACS
Dept. of Neurosurgery,
Carolina Neurosurgery and Spine
Associates, Charlotte, NC
Stuart H. Burri, MD Dept. of Radiation Oncology,
Carolinas Medical Center, Charlotte,
NC
Charles S. Cobbs, MD Dept. of Neurosciences,
California Paciﬁc Medical Center,
San Francisco, CA
Laurie E. Gaspar, MD Dept. of Radiation Oncology,
University of Colorado-Denver,
Denver, CO
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Dept. of Neurological Surgery,
University of Pittsburgh Medical
Center, Pittsburgh, PA
Mark E. Linskey, MD Dept. of Neurosurgery,
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University of Wisconsin School of
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Tom Mikkelsen, MD Dept. of Neurology,
Henry Ford Health System, Detroit, MI
Jeffrey J. Olson, MD Dept. of Neurosurgery,
Emory University School of Medicine,
Atlanta, GA
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Northshore University Health System,
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Barrow Neurological Institute,
Phoenix, AZ
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extracted by one reviewer and the extracted information
was checked by a second reviewer. The PEDro scale [2, 3]
was used to evaluate the methodological quality (internal
validity) of randomized trials. The quality of comparative
studies using non-randomized designs was evaluated using
eight items selected and modiﬁed from existing scales
(Appendix B).
Evidence and summary tables, reporting the extracted
study information and quality assessment, were generated
for all of the included studies for each of the eight ques-
tions. Meta-analyses were undertaken when sufﬁcient data
for pooling was available for the outcomes of interest. In
only one of the eight guideline papers in this series was the
criteria for pooling met. The speciﬁc details of the meta-
analyses undertaken for this question are provided in the
whole-brain radiation therapy (WBRT) guideline paper by
Gaspar et al. [4].
Evidence classes and levels of recommendations
endorsed by the AANS/CNS
Both the evidence classiﬁcation and the strength of the
recommendations were graded according to the criteria
endorsed by the AANS/CNS (Table 5). The class of evi-
dence assigned to each study was based on study design
alone (i.e., class I, II, or III). The strength of the
recommendations made (i.e., level 1, 2, or 3) took into
account aspects of study quality, not just study design.
Speciﬁcally, the level of a recommendation made could be
decreased, based on consensus input, if there were meth-
odological concerns regarding the studies that provided
evidence for that particular recommendation.
Guideline panel consensus and practice guideline
approval process
Small writing groups composed of four to eight members
of the clinical guideline panel were assigned to each of the
eight questions, and each question had at least one member
from each subspecialty as part of the initial writing team.
Each group was provided with the included studies and the
evidence/summary tables for their speciﬁc question, as well
Table 5 AANS/CNS evidence classes and levels of recommendation
Evidence classiﬁcation
Class I Evidence provided by one or more well-designed
randomized controlled clinical trials, including
overview (meta-analyses) of such trials
Class II Evidence provided by well-designed observational
studies with concurrent controls
(e.g. case control and cohort studies)
Class III Evidence provided by expert opinion, case series,
case reports and studies with historical controls
Levels of recommendation
Level 1 Generally accepted principles for patient management,
which reﬂect a high degree of clinical certainty
(usually this requires Class I evidence which directly
addresses the clinical questions or overwhelming
Class II evidence when circumstances preclude
randomized clinical trials)
Level 2 Recommendations for patient management
which reﬂect clinical certainty (usually this requires
Class II evidence or a strong consensus
of class III evidence)
Level 3 Other strategies for patient management for
which the clinical utility is uncertain
(inconclusive or conﬂicting evidence or opinion)
AANS, CNS and AANS/CNS Joint Tumor Section 
decide to develop evidence-based guidelines on the 
management of brain metastases
Formation of the clinical 
expert guideline panel
Partner with the McMaster 
EPC to conduct the 
systematic literature review 
Topic Refinement: 
Scope of questions to be addressed and 
establishment of eligibility criteria
Literature search, study selection, data 
extraction, quality assessment,
and creation of evidence tables
Writing groups for each question draft 
clinical practice guidelines
Circulation of the draft guidelines to 
entire guideline panel for feedback, 
discussion and consensus 
Guidelines presented to the JGC for 
review and approval 
AANS Board, CNS Executive 
Committee and AANS/CNS Joint Tumor 
Section Executive Committee review the 
guidelines for endorsement decision 
Submission of the guidelines to the 
Journal of Neuro-Oncology for 
publication
Fig. 1 Overview of the guideline development process
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123as an exhaustive statistical analysis, from the McMaster
EPC team. Using this information, the small writing groups
were responsible for drafting the clinical practice guideline
for their respective questions. The draft guidelines were
then circulated to the entire clinical guideline panel for
feedback, discussion, and ultimately approval.
In accordance with the initial goal of a 1-year time
horizon, the completed evidence-based clinical practice
guidelines on the management of brain metastases were
presented to the Joint Guidelines Committee (JGC) of the
AANS/CNS for approval approximately 12 months after
starting the evidence review process. As part of their
approval process, the JGC could provide input on the
content of the clinical practice guidelines. Once approved
by the American Association of Neurological Surgeons and
the Congress of Neurological Surgeons, the guidelines
were also presented to the executive leadership of the
Society for Neuro-oncology (SNO), the American Society
for Radiation Oncology (ASTRO), in addition to the
AANS/CNS Joint Tumor Section, to offer multidisciplin-
ary review and endorsement with plans for online publi-
cation and dissemination in all of the various organized
societies concerned with the treatment of brain metastases.
Development of this set of evidence-based clinical prac-
tice guidelines was editorially independent fromthe funding
agencies. The funding agencies (AANS Board, CNS Exec-
utive Committee, and AANS/CNS Joint Tumor Section
Executive Committee) review of these guideline papers,
following JGC approval but prior to submission for publi-
cation, was limited to whether or notto endorse or reject this
bodyofwork.Figure 1providesanoutlineofthekeystepsin
the process of developing these clinical practice guidelines.
Plans for updating the guidelines
Searches of a clinical trial registry (clinicaltrials.gov) iden-
tiﬁed several on-going randomized trials that are evaluating
treatment comparisons directly addressed by questions in
this guideline series. The outcome of these trials will be
monitored and updates to the relevant guidelines will be
undertaken as new evidence develops and as clinical need
indicates.
Acknowledgments We would like to acknowledge the contribu-
tions of the McMaster Evidence-based Practice Center (EPC), Dr.
Parminder Raina (Director). Dr. Lina Santaguida (Co-Associate
Director, Senior Scientist) led the EPC staff. We would like to
acknowledge the following EPC staff, Maureen Rice, Librarian,
Rachel Morris, Research Assistant, and Mary Gauld, Senior Research
Manager. The EPC staff were responsible for managing the system-
atic review process, searching for and retrieving, reviewing, data
abstraction of all articles, preparation of the tables and the formatting
and editing of the ﬁnal manuscripts.
Disclaimer of liability The information in these guidelines reﬂects
the current state of knowledge at the time of completion. The pre-
sentations are designed to provide an accurate review of the subject
matter covered. These guidelines are disseminated with the under-
standing that the recommendations by the authors and consultants
who have collaborated in their development are not meant to replace
the individualized care and treatment advice from a patient’s physi-
cian(s). If medical advice or assistance is required, the services of a
competent physician should be sought. The proposals contained in
these guidelines may not be suitable for use in all circumstances. The
choice to implement any particular recommendation contained in
these guidelines must be made by a managing physician in light of the
situation in each particular patient and on the basis of existing
resources.
Disclosures All panel members provided full disclosure of conﬂicts
of interest, if any, prior to establishing the recommendations con-
tained within these guidelines.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
Appendix A: Medline search strategy
See Table 6.
Appendix B: Quality assessment criteria
See Table 7.
Table 6
Search strategy used for the Medline database
1. exp Brain Neoplasms/
2. Central Nervous System Neoplasms/
3. or/1–2
4. (metasta$ or secondary).tw.
5. exp Neoplasm Metastasis/
6. or/4–5
7. 3 and 6
8. exp Brain Neoplasms/sc [Secondary]
9. ((metasta$ or secondary) adj3 (brain or cereb$ or intercranial)).tw.
10. or/8–9
11. 7 or 10
12. animals/not (animals/and humans/)
13. 11 not 12
14. limit 13 to yr = ‘‘1990–2008’’
15. limit 14 to english language
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Table 7
Quality assessment of randomized studies using the PEDro
criteria [2, 3]
1. Eligibility criteria speciﬁed?
2. Random allocation?
3. Allocation concealed?
4. Groups similar at baseline on most important prognostic indicators?
5. Subjects blinded to treatment?
6. Blinding of clinicians who administered treatment?
7. Blinding of assessors who measured at least 1 key outcome?
8. Measures of at least 1 key outcome from more than 85% subjects
initially allocated to groups?
9. All subjects for whom outcome measures were available received
the treatment or control condition as allocated or data was analyzed
by ‘‘intention to treat’’?
10. Results of between-group statistical comparisons are reported for
at least one key outcome?
11. Study provides both point measures and measures of variability
for at least 1 key outcome?
Quality assessment of non-randomized studies
1. Are the respective study arms comparable on the basis of the design
or analysis?
2. Is the selection of the study arms appropriate?
3. Were the eligibility criteria the same for all of the study arms?
4. Does the study report whether or not participants received
additional interventions that may inﬂuence the results (e.g.
additional treatment for recurrent/progressive brain metastases)?
5. Was there adequate adjustment for confounding in the analyses
from which the main ﬁndings were drawn?
6. Are the interventions of interest clearly described?
7. Were the study subjects in different intervention groups recruited
over the same period of time?
8. Is the follow-up of the groups adequate?
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